In January 2018, Scott Gottlieb, the Commissioner of the US Food and Drug Administration (FDA), stated that the agency would “look for ways to be more forthcoming with the information” it holds “within the boundaries” of its governing laws.1 Gottlieb announced a voluntary initiative under which the agency would begin to publish clinical study reports prepared by companies in support of new drug applications. Clinical study reports summarize the protocols and findings from all clinical studies for a given drug thus providing more detail about a drug’s safety and effectiveness than is often found in the medical literature.2 Gottlieb also announced a related initiative to integrate clinical trial identifiers, used in Clinicaltrials.gov and other trial registries, into FDA documentation, including advisory committee materials, approval letters, and product labels.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Herder M. Reviving the FDA’s Authority to Publicly Explain Why New Drug Applications Are Approved or Rejected. JAMA Intern Med. 2018;178(8):1013–1014. doi:10.1001/jamainternmed.2018.3137
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: